Craif Inc.
Craif provides non‑invasive, urine‑based tests to detect multiple cancers at an earlier, more treatable stage. The company combines proprietary exosome collection with a curated microRNA database and machine‑learning algorithms to identify cancer‑specific signatures. Its flagship MySignal test screens for seven cancers, and Craif is developing an IVD pancreatic cancer test for high‑risk populations while running clinical validation in Japan and the U.S. Craif operates as a molecular diagnostics biotechnology company working with hospitals and research centers to commercialize tests and pursue regulatory approval and reimbursement in major markets.
Craif Inc.
Craif provides non‑invasive, urine‑based tests to detect multiple cancers at an earlier, more treatable stage. The company combines proprietary exosome collection with a curated microRNA database and machine‑learning algorithms to identify cancer‑specific signatures. Its flagship MySignal test screens for seven cancers, and Craif is developing an IVD pancreatic cancer test for high‑risk populations while running clinical validation in Japan and the U.S. Craif operates as a molecular diagnostics biotechnology company working with hospitals and research centers to commercialize tests and pursue regulatory approval and reimbursement in major markets.